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Introduction: Cancer has become the third cause of death in Mexico. Treatment for 
cancer is often complex and lengthy. New and better medicines enter the market 
at high prices, which may limit access. Like most Latin American countries, Mexico 
has an essential cancer medicines list that includes innovative medicines. Their 
accessibility and use in the public sector remain unknown.
Objective: To describe the use, as a proxy of access, of innovative and essential 
cancer medicines in the public sector in Mexico, by insurance institution, and by 
five regions between 2010 to 2016.
Methods: We used drug utilization research methods to assess the use of eight 
patented cancer medicines. Through the national transparency platform, we 
obtained data on the quantities of these medicines used in all public health 
facilities and social health insurance institutions and recalculated those figures 
into defined daily dose (DDD) per 1000 population per year.
Results: Overall, the use of all medicines increased over the years, especially for 
trastuzumab, rituximab, and imatinib. The use of innovative medicines was higher 
per population covered in social health insurance institutions than in governmental 
facilities. Throughout the study period, the central region (including Mexico City) 
has used more medicines per population than the other regions.
Conclusions: The use and access of some essential innovative cancer medicines 
have increased over the years but remains unequal across insurance schemes and 
regions. Particularly, the Ministry of Health Insurance scheme and northern and 
western regions in the country would benefit from additional efforts to increase 
access to essential cancer medicines.
Keywords: Access, Drug utilization, Essential cancer medicines, Mexico, Insurance 
schemes access, Regional access
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Introduction
Cancer has become a leading cause of disability and mortality in the world, 
particularly in low- and middle-income countries (LMICs).1-3 Such healthcare 
systems are not yet prepared to handle this burden.4 In 2013, 12.8% of all deaths 
in Mexico were due to cancer.5 Although Mexico has introduced specific health 
policies to tackle non-communicable diseases, like tobacco control, obesity control, 
and breast cancer screening, cancer remains the third leading cause of death in 
the country.5 Like other Latin American (LATAM) countries, Mexico has invested 
significant resources to enhance preventive efforts - as many cancer cases are 
diagnosed at advanced stages - which typically have poor prognosis and high 
mortality.5 Yet, factors such as lack of awareness on the importance of screening, 
poor distribution of screening programs, delays in pathology assessment and 
referrals, poverty, geographic barriers, lack of access to healthcare systems, 
financial barriers, and stigma related to cancer have negatively impacted the 
improvement of cancer treatments and its outcomes.1,4-7 In addition, cancer cases 
diagnosed at later stages of the disease consume more resources, as treatments 
tend to be more complex.1,5,8
In Mexico, the public sector provides most of the cancer care including cancer 
medicines.9 This sector consists of five different social health insurance (SHI) 
institutions, each with their independent facilities and managerial styles, 
responsible for providing health coverage and care to the formal sector (employees 
and their families). The Mexican Social Security Institute (IMSS) is the main SHI 
institution, providing coverage to employees of private companies, approximately 
46% of the population. The Institute for Social Security and Services for State 
Workers (ISSSTE) provides coverage to state employees, approximately 10% 
of the population. The National Defense Ministry (SEDENA), the Navy Ministry 
(SEMAR) and the National Oil Company (PEMEX) provide coverage to their 
employees, approximately 2% of the population.10 These institutions cover cancer 
treatment according to their own guidelines, policies and medicine formularies. 
The population without SHI (roughly 42%) can receive healthcare at the Ministry 
of Health (MoH) facilities; each facility has its own policies and managerial style. 
Most of this population is affiliated to the People’s Health Insurance (Seguro 
Popular de Salud, SPS), which is a government insurance that reimburses health 
institutions according to a catalogue of interventions.11 SPS covers all child cancer 
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types and some of the most prevalent adult types, following its own guidelines 
and protocols. The MoH facilities have a list of selected medicines based on the 
national formulary and/or according to the list of medicines covered by SPS as 
described in its catalogue of interventions, which is also based on the national 
formulary.11-13
The innovation field for cancer medicines is growing.14,15 New and better medicines 
are coming into the market, forcing constant updates of treatment protocols and 
formularies. Yet, most of the time, the high prices tagged to these innovations 
keep newer treatments unaffordable for individual patients4 and burdensome 
for health systems, thus limiting patient’s access to new cancer medicines.16,17 
As a result, prices rather than efficacy become a decisive factor for inclusion 
of these medicines in national or institutional formularies and ultimately, for 
reimbursement.1,18
Access to new cancer medicines is a challenge in all LMICs.19 Most LATAM 
countries – including Mexico – utilize essential medicines lists for procurement 
purposes,1 which should guarantee proper access in health centers.20 However, 
differences in access to these medicines across insurance schemes and country 
regions are not well known.21 For example, some European countries and Australia 
have performed drug utilization studies to describe the availability and utilization 
of these medicines across regions and countries. These methodologies can inform 
about the distribution and the uptake of resources (e.g. cancer medicines); but 
these methodologies have rarely been used in middle-income countries (MICs), 
including Mexico.19,22-24 Therefore, this study describes the use of patented cancer 
medicines in the Mexican public sector, comparing five SHI schemes and the MoH 
in five geographic regions, and changes between 2010 and 2016.
Methods
Cancer medicines studied
We selected medicines based on the following criteria: inclusion in the national 
formulary, coverage by the SHI institutional lists, coverage by SPS, inclusion in the 
national clinical guidelines and SPS treatment guidelines (protocols), and patent 
protection in Mexico until after 2017. We narrowed our selection of medicines based 
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on the criterion that medicines should have gone through price negotiations every 
year from 2010-2016 by the Mexican Coordinating Commission for Negotiation of 
Prices of Medicines (CCNPMIS).25 The CCNPMIS is a commission that negotiates 
directly with pharmaceutical companies the public procurement prices applicable 
for the public sector only. The CCNPMIS determines which medicines will be 
considered for negotiations taking into consideration their relevance, estimated 
demand, and procurement volume.25,26 The latter characteristics indicate that 
these medicines are considered both innovative and essential in Mexico and 
that they could have been procured in the public sector during that period of 
time. Following these criteria, we selected the following medicines: bevacizumab, 
dasatinib, imatinib, nilotinib, rituximab, sorafenib, sunitinib, and trastuzumab. Some 
of these medicines (nilotinib and sorafenib) are not covered by SPS; furthermore, 
some of these are covered by SPS only for children or could be covered in case 
of disease progression (bevacizumab, dasatinib, sunitinib). We decided to include 
them because they had been negotiated by the CCNPMIS and included in the 
national clinical guidelines.
This range of medicines reflects some of the main cancers prevalent in Mexico. 
Imatinib, dasatinib, and nilotinib are indicated for leukemia,27 the most prevalent 
cancer in children in Mexico.28 Rituximab is indicated for non-Hodgkin lymphoma 
(NHL) treatment in addition to leukemia. Trastuzumab is indicated for breast 
cancer, one of the most common causes of death among women in Mexico.29 
Bevacizumab, one of the most frequently used anti-cancer medicines worldwide, 
is indicated as a first line treatment for advanced colorectal cancer,30,31 which has 
an increasing incidence in Mexico.32 Sorafenib and sunitinib are both indicated for 
renal cancer; sunitinib is covered by SPS only for children.
Measures and procedure
Procurement data (volume and value) from the public sector were retrieved through 
the National Transparency Platform (PNT).33 Procurement data from all possible 
public health institutions providing cancer care in the country were obtained from 
the various institutions that provide this type of care (see Table 4.1).
We used the defined daily dose (DDD) as the unit of measurement of use, in order 
to standardize and add the quantities procured and allow for proper comparisons. 
Because the World Health Organization (WHO) has not yet defined DDDs for most 
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cancer medicines we used DDD values as reported by the German national 
Anatomic-Therapeutic-Chemical classification.34
To measure the use or utilization rates of these medicines among the five 
SHI institutions and the MoH, population numbers affiliated to each type of 
health provider were used, as reported by the National Institute of Statistics 
and Geography (INEGI).10 To measure access among geographic regions, state 
population affiliated to SPS data were used, as reported by the SPS.35
Table 4.1. Public Health Institutions and Social Health Insurance Institutions providing cancer 
care in Mexico
Ministry of Health (MoH)
Each states’ Ministry of health and/or state health services (SESA)
Mexican Social Security Institute (IMSS)
Institute for Social Security and Services for State Workers (ISSSTE)
National Defense Ministry (SEDENA)
Navy Ministry (SEMAR)
National Oil Company (PEMEX)
National Institute of Cancerology (INCAN)
National Nutrition Institute (INNSZ)
National Institute of Pediatrics (INP)
Federal Hospitals
Regional high specialty hospitals (HRAE)
Data analysis
Standard drug utilization research methods were used.36 First, we analyzed the 
data on the eight medicines from 2010-2016 separately, in order to assess 
their individual use rates in DDDs/1000 inhabitants. Secondly, we expressed 
differences in access according to health insurance schemes as DDDs/1000 
persons covered. We also compared access between the regions for MoH channels 
only, regrouping 32 states into five regions37 (Figure 4.1) and expressing overall 
access to all products together as total DDDs/1000 inhabitants per region. We 
regrouped the country into 5 geographical regions following our own discretion 
into the northern, center, western, eastern and southern regions, derived from 
the Ministry of Education’s classification.38
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Figure 4.1. Mexico – the five regions of study.
Region 1 (North): Baja California, Baja California Sur, Chihuahua, Coahuila, Durango, Nuevo Leon, Sinaloa, Sonora, 
Tamaulipas
Region 2 (Center): Mexico City, Mexico State, Guanajuato, Morelos, Queretaro, San Luis Potosi, Zacatecas
Region 3 (West): Aguascalientes, Colima, Guerrero, Jalisco, Michoacan, Nayarit
Region 4 (East): Hidalgo, Puebla, Tlaxcala, Veracruz
Region 5 (South): Campeche, Chiapas, Oaxaca, Quintana Roo, Tabasco, Yucatan
Results
Differences in access to innovative cancer medicines in Mexico
Figure 4.2 shows quantities procured of the eight-selected cancer medicines from 
2010-2016 in public facilities in Mexico. Overall, the annual quantities procured 
have increased for all medicines under study. The most commonly used medicines 
were imatinib, rituximab, and trastuzumab. The quantities of rituximab and imatinib 
have remained high throughout the years, while trastuzumab shows a considerable 
increase since 2012 and a decrease between 2015 and 2016. The quantities of 
bevacizumab, dasatinib, nilotinib, sorafenib, and sunitinib have remained steadily 
increasing, but in much lower quantities.
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Figure 4.2. Annual quantities of eight innovative essential cancer medicines procured in the 
public sector (SHI institutions and MoH) in Mexico (2010-2016)
Access to innovative cancer medicines in the public sector
Figure 4.3 shows that quantities of innovative cancer medicines procured by 
different SHI institutions and the MoH have increased over the years (especially 
since 2013). The quantities of medicines procured by IMSS and the MoH have 
remained lower than by other SHI institutions in the period of study. Among SHI 
institutions, ISSSTE has procured larger quantities than all other institutions. 
IMSS procured the largest volume of medicines, but when adjusted to quantities 
procured per population covered (approximately 50%), it has the lowest rates 
among the five SHI institutions. The SHI for the oil company (PEMEX), the army 
(SEDENA), and the navy (SEMAR) have increased their use the most since 2011, 
and have had constantly higher quantities per population covered than IMSS and 
MoH.
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Figure 4.3. Total annual quantities of eight innovative essential cancer medicines procured 
in the Mexican public sector (SHI institutions and MoH) per insurance scheme (2010-2016)
*1000 inhabitants covered per SHI institution and by the MoH/SPS; for abbreviations see Table 1.
Regional quantities of innovative cancer medicines
Figure 4.4 shows that quantities of innovative cancer medicines procured by the 
MoH remained lower in the northern, western, eastern and southern regions than 
in the central region (including Mexico City). In all regions, quantities have remained 
largely the same from 2010-2013. From 2013 to 2015, most regions experienced 
an increase, particularly the central region. However, the western and the southern 
regions experienced a decrease in the quantities of medicines procured since 
2014 and 2015 respectively.
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Figure 4.4. Total annual quantities of eight innovative essential cancer medicines purchased 
in MoH facilities per region (2010-2016)
 *1000 inhabitants covered by SPS per region
Discussion
To our knowledge, this is the first study to describe the use of cancer medicines 
across the Mexican public sector. Reporting use of medicines provides a proxy 
measure of access to medicines and allows for comparisons between different 
settings (e.g. insurance schemes, geographical regions). First, the amount of 
DDDs of rituximab, imatinib, and trastuzumab account for more than 70% of the 
total of DDDs of all procured medicines under study. Second, SHI institutions 
provide larger quantities per insured population than the MoH. Third, the central 
region (including Mexico city) reports, on average, constantly higher use of cancer 
medicines than the other regions, which continued to have a low level of use.
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Access barriers to individual medicines
All medicines under study showed an increase in quantities procured throughout 
2010-2016. For most of them, this increase was slow and only for some 
medicines, in particular, imatinib, rituximab, and trastuzumab, the increase was 
larger. These three medicines were covered by all SHI institutions and by the SPS. 
These medicines have demonstrated improved health outcomes,21 which has been 
recognized by the WHO and justifies their inclusion in the WHO Essential Medicines 
List (EML) since 2015.21 However, only SPS does not fully cover dasatinib, nilotinib, 
bevacizumab, sunitinib and sorafenib.27 Low accessibility of effective innovative 
medicines could limit adequate cancer care,16 particularly for the most vulnerable 
populations with colorectal and renal cancer.
Use and access to new cancer medicines is low in Mexico, with levels similar to 
those reported from other developing regions such as, for example, Africa, South-
East Asia, and LATAM.39-41 Studies performed on the use of some innovative 
medicines in the USA, Russia, Turkey, Brazil, and Mexico42,43 have reported that 
barriers to access and use of innovative cancer medicines link to limited coverage 
by public insurance schemes, inclusion in the EML, availability of the medicine at 
the facilities, and updated clinical guidelines. The lack of availability in the public 
sector has pushed patients in Mexico, Russia, and Brazil to get these medicines 
in the private sector and pay out of pocket.42,43
Access barriers by health coverage
We found large differences in use linked to the type of health coverage. For 
example, all eight medicines studied were covered by all SHI institutions (IMSS, 
ISSSTE, PEMEX, SEDENA, SEMAR) but only three were covered by the governmental 
SPS for children and adults (imatinib, rituximab, trastuzumab), and another two 
medicines where covered by SPS only for children (dasatinib and sunitinib), 
therefore limiting use of the other medicines in the MoH facilities.27 Other studies 
have consistently reported higher availability and accessibility rates for essential 
medicines at the IMSS than other institutions in the public sector.44-48 Previous 
research reported that MoH and IMSS are the largest providers of cancer care 
in the country;9 despite this, access to the medicines of study at these two 
institutions32 remained lower than at the other SHI institutions when expressed as 
quantities used per population insured. High prices of medicines, financial barriers, 
budget constraints, and the lack of prioritization of cancer care could explain the 
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differences among institutions, highlighting the inequalities in access to innovative 
medicines and healthcare.16,32 This is worrisome as it could indicate that over 80% 
of the population experiences barriers to innovative medicines that could provide 
them with better outcomes of their treatment against cancer.
Access barriers by geographic location
We found regional variations in the use of the studied medicines, in line with 
previous findings from other countries.24,31,49-51 These variations could be due to 
differences in the burden of disease, budget and resource allocation, purchasing 
power, differences in capacity within the healthcare system and disease 
priorities.16,36,52 Like other LATAM countries, Mexico concentrates resources 
and health care in big cities (e.g. Mexico City, Monterrey and Guadalajara in the 
central, northern and western regions respectively). Such a policy generates an 
“overwhelming influx of patients”,1,53 which may have led to the relatively large 
increase in provision in recent years. Based on the number of hospital discharges, 
these three regions reported high proportions of cancer patients attended by 
the MoH.9,54 Yet, use is far greater in the central region than in all other regions. 
In addition, distance to health facilities and traveling costs prevent patients 
from seeking healthcare and getting treatment.32,55-57 Thus, decentralization of 
healthcare is needed to bring treatment closer to patients, and improve access 
and health outcomes in regions currently lagging behind.
We also found a decrease in the quantities of medicines procured at MoH facilities 
in 2016, particularly in the central and western regions, largely explained by 
decreased quantities of trastuzumab. Trastuzumab had experienced constant 
increases in use particularly from 2012 to 2015 and had a sudden drop in 2016 
(Figure 2). This finding is unexpected since Mexico has invested efforts in the 
control of breast cancer.29,58 The reasons for this decrease and the possible 
barriers that MoH facilities face when procuring trastuzumab need to be further 
explored.
Research in the US, Australia, China, Canada, and Sweden suggest that geographic 
variations in access to innovative medicines23,24,31,49-51 could be explained by 
differences in coverage, insurance guidelines and management of the disease, 
professional disagreement, and prescription preferences, budget issues and local 
policies. Heterogeneity in the burden of disease can also influence the allocation 
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of resources to a specific type of medicines.16,23 In the case of China, regional 
differences were also attributable to differences in access to healthcare.49
Strengths and limitations
The strength of this study lies in the collection of data from all public health 
institutions in the whole country, which allowed for a comprehensive overview on 
procurement and use of the selected medicines and for presenting differences 
between geographic regions and insurances schemes. Potential limitations include 
that we were unable to retrieve data from some states (e.g. Michoacan) while some 
other states provided incomplete data (e.g. Nayarit, Quintana Roo, Nuevo Leon, 
Guerrero), particularly before 2014. Our regional results (particularly northern, 
western and southern regions) may, therefore, underestimate the real quantities. 
Another limitation is that we did not take into account any regional variations 
in the cancer burden, which could affect the quantities of medicines needed. 
Furthermore, this study focused on a selected number of innovative cancer 
medicines and does not account for a whole treatment scheme and does not 
differentiate use according to the burden of each disease. Further research should 
focus on complete treatment schemes and weigh the use of these medicines 
against the burden of diseases (e.g. using mortality, incidence and/or morbidity 
data).
Implications
At the organizational level, the use of medicines through IMSS and the MoH was 
lower than through other SHI institutions. Since IMSS and the MoH together cover 
most of the population, a more detailed analysis is needed to identify the barriers 
preventing adequate use and access to cancer essential medicines. Differences 
between regions continue to reflect a concentration of resources in the center of 
the country and limited infrastructure to manage specialized healthcare needs in 
the rest of the regions.
Previous research on access to innovative cancer medicines in LMICs has focused 
on whether these are included in national EMLs.20,59 Further research should now 
focus on the use and actual access to comprehensive treatment schemes of the 
most prevalent types of cancer,20 in order to inform stakeholders and policymakers 
on the current situation and identify potential barriers to be addressed. Public 
health institutions and the government need to reflect on how resources can be 
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allocated more equally and efficiently to ensure universal access to the most 
cost-effective level of care. Improving access and use of innovative treatments of 
which the effectiveness, safety, and cost-effectiveness have been established will 
provide a better quality of cancer care, better health outcomes and fewer deaths 
due to cancer.50,52 The government should monitor the needs for these medicines 
along with their actual use and access to guarantee the best level of care. Efforts 
on improving access to cancer medicines need to go along with better access to 
screening, prevention and other types of treatment.
Conclusions
Over the last six years, the use of eight innovative essential cancer medicines 
has increased in Mexico, particularly of imatinib, rituximab, and trastuzumab. 
The use of five other essential cancer medicines has remained low due to 
insufficient insurance coverage. Regional differences in the use of innovative 
cancer medicines highlight inequalities in access to cancer care. Providing access 
to essential innovative cancer medicines remains a challenge in Mexico. Further 
decentralization of cancer care is warranted to improve equitable access and use 
of effective and affordable cancer treatments.
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